Drug Pricing Takes Over User Fee Hearing – And That Might Be Good News For Industry

 
• By Michael McCaughan
  
Not so bad news
Drug pricing discussions during an FDA hearing are not necessarily always bad news. • Source: Alamy

More from Pricing Debate

More from Market Access